H. Lundbeck A/S (CPH:HLUN.B)

Denmark flag Denmark · Delayed Price · Currency is DKK
44.78
+0.28 (0.63%)
At close: Dec 5, 2025
2.00%
Market Cap 42.14B
Revenue (ttm) 24.08B
Net Income (ttm) 3.81B
Shares Out 991.23M
EPS (ttm) 3.84
PE Ratio 11.59
Forward PE 7.58
Dividend 0.95 (2.13%)
Ex-Dividend Date Mar 27, 2025
Volume 275,475
Average Volume 763,162
Open 44.18
Previous Close 44.50
Day's Range 44.18 - 45.12
52-Week Range 27.20 - 47.78
Beta 0.38
RSI 51.19
Earnings Date Nov 12, 2025

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]

Sector Healthcare
Founded 1915
Employees 5,707
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol HLUN.B
Full Company Profile

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.

Financial Statements

News

There is no news available yet.